NASDAQ:PVLA Palvella Therapeutics (PVLA) Stock Price, News & Analysis $24.12 +0.29 (+1.22%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Palvella Therapeutics Stock (NASDAQ:PVLA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Palvella Therapeutics alerts:Sign Up Key Stats Today's Range$23.90▼$26.0050-Day Range$20.51▼$26.6352-Week Range$6.20▼$29.27Volume40,233 shsAverage Volume132,679 shsMarket Capitalization$266.77 millionP/E RatioN/ADividend YieldN/APrice Target$46.29Consensus RatingBuy Company Overview Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. Read More Palvella Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScorePVLA MarketRank™: Palvella Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 302nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingPalvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalvella Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Palvella Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Palvella Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palvella Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palvella Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalvella Therapeutics has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Palvella Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PVLA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalvella Therapeutics does not currently pay a dividend.Dividend GrowthPalvella Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PVLA. News and Social Media3.0 / 5News Sentiment1.31 News SentimentPalvella Therapeutics has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Palvella Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PVLA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Palvella Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,325.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.50% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Palvella Therapeutics' insider trading history. Receive PVLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PVLA Stock News HeadlinesPalvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $46.29 Average PT from AnalystsJuly 6 at 2:09 AM | americanbankingnews.comPalvella Therapeutics Added to Russell 3000® and Russell 2000® IndexesJune 30, 2025 | globenewswire.com140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, Apple, and Amazon. And for the July 4th holiday...I'm sharing this secret for just $9.July 6 at 2:00 AM | Investors Alley (Ad)PVLA - Palvella Therapeutics Inc Key Metrics - MorningstarJune 27, 2025 | morningstar.comMPVLA - Palvella Therapeutics Inc Executives - MorningstarJune 26, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - MorningstarJune 24, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - NasdaqJune 24, 2025 | nasdaq.comPalvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN RapamycinJune 24, 2025 | msn.comSee More Headlines PVLA Stock Analysis - Frequently Asked Questions How have PVLA shares performed this year? Palvella Therapeutics' stock was trading at $12.00 at the start of the year. Since then, PVLA stock has increased by 101.0% and is now trading at $24.12. How were Palvella Therapeutics' earnings last quarter? Palvella Therapeutics, Inc. (NASDAQ:PVLA) posted its earnings results on Thursday, May, 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $2.66. Read the conference call transcript. How do I buy shares of Palvella Therapeutics? Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2025Today7/06/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PVLA Previous SymbolNASDAQ:PVLA CIK1583648 Webwww.pieris.com Phone857-246-8998Fax49-8161-141-1444EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$46.29 High Stock Price Target$52.00 Low Stock Price Target$38.00 Potential Upside/Downside+91.9%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($12.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.29% Return on Assets-43.30% Debt Debt-to-Equity RatioN/A Current Ratio8.84 Quick Ratio8.84 Sales & Book Value Annual Sales$42.81 million Price / Sales6.23 Cash FlowN/A Price / Cash FlowN/A Book Value$5.58 per share Price / Book4.32Miscellaneous Outstanding Shares11,060,000Free Float8,790,000Market Cap$266.77 million OptionableN/A Beta-0.11 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:PVLA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.